Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

1.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.8K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

610
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
610
Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

2.6K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
2.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

377
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
377

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Nanopore sequencing with proteins: synchronization and dischronization of molecular dynamics simulations with laboratory and industrial developments.

Soft matter·2026
Same author

Identification of Immune-Related Diagnostic Genes and Subtypes of Active Ulcerative Colitis.

Iranian journal of allergy, asthma, and immunology·2026
Same author

Integrated multi-omics and single-cell analyses identify metabolic heterogeneity and therapeutic vulnerabilities in medullary thyroid cancer.

British journal of cancer·2026
Same author

Slow Dissociation of Nitazenes from the <i>μ</i>-Opioid Receptor Underlies the Challenge of Overdose Reversal.

bioRxiv : the preprint server for biology·2026
Same author

Specific GPCRs elicit unique extracellular vesicle miRNA array signatures.

eLife·2026
Same author

Proteogenomic characterization delineates clinically relevant subtypes of advanced differentiated thyroid cancer.

Cell reports. Medicine·2026
Same journal

Molecular pharmacology of mGlu<sub>7/8</sub> heterodimers reveals unique properties of orthosteric agonists and positive allosteric modulators.

Molecular pharmacology·2026
Same journal

Effects of ivermectin on the activation and desensitization of the human GABA<sub>A</sub> receptor.

Molecular pharmacology·2026
Same journal

Corrigendum to "Amantadine derivative Amt-1 enhances antiviral defense against influenza A virus via Nrf2/HO-1 pathway" [Molecular Pharmacology 108 (2026) 100099].

Molecular pharmacology·2026
Same journal

G protein-coupled receptor kinase 3 couples atypical chemokine receptor 4 independent of G proteins.

Molecular pharmacology·2026
Same journal

Structural and molecular determinants of glutamate transporter allosteric modulators.

Molecular pharmacology·2026
Same journal

Role of GPR55 in glutamatergic and dopaminergic signaling: A review of preclinical evidence in neuropsychiatric disorders.

Molecular pharmacology·2026
関連記事をすべて見る

関連する実験動画

Updated: Sep 10, 2025

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
07:30

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry

Published on: November 21, 2012

13.9K

トレースアミン関連受容体1アゴニストは,ドーパミントランスポーター機能を差異的に調節する.

Julia K Huey1, Xiao Shi2, William E Schutzer3

  • 1Program in Physiology and Pharmacology, Department of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, Oregon; Department of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, Oregon.

Molecular pharmacology
|August 21, 2025
PubMed
まとめ
この要約は機械生成です。

トレースアミン関連受容体1 (TAAR1) アゴニストは,ドーパミントランスポーター (DAT) にさまざまな効果を示します. これらのTAAR1アゴニストがDAT機能とトラフィックに及ぼす影響の違いは,治療設計において臨床的に重要である.

キーワード:
アンフェタミンドーパミントランスポータートレースアミン関連受容体1

さらに関連する動画

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.4K
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

25.9K

関連する実験動画

Last Updated: Sep 10, 2025

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
07:30

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry

Published on: November 21, 2012

13.9K
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.4K
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

25.9K

科学分野:

  • 神経科学
  • 薬理学について

背景:

  • ウロタロンを含むトレースアミン関連受容体1 (TAAR1) アゴニストは,神経精神疾患について研究されています.
  • ULOTARONTの臨床抗精神病効果は,第3相試験でプラセボと同等であり,TAAR1アゴニストメカニズムに関する疑問を提起した.

研究 の 目的:

  • ドーパミントランスポーター (DAT) でのTAAR1アゴニストRO5166017,RO5256390およびウルタロントの薬理学を調査する.
  • 異なるTAAR1アゴニストがDAT機能とドーパミンホメオスタシスに異なった影響を及ぼすという仮説を検証する.

主な方法:

  • RO5166017,RO5256390およびウロタロンに対するDATにおけるドーパミン吸収の直接結合および抑制を評価した.
  • 培養細胞と歯類のシナプトソームにおけるドーパミン吸収とアンフェタミン誘発ドーパミン放出に対するTAAR1依存的効果を評価した.
  • 細胞表面のDAT濃度の変化を測定するために表面バイオチニレーションを使用した.

主要な成果:

  • RO5166017とRO5256390は,DAT経由でドーパミンの吸収を直接抑制したが,ウルターントはそうしなかった.
  • RO5166017はドーパミンの吸収を増加させ,ULOTARONTとRO5256390は,TAAR1に依存した方法で,ドーパミンの吸収を減少させた.
  • RO5166017 細胞表面のDATとアンフェタミン誘発のドーパミン流出が増加し,その効果はTAAR1の活性化に依存する.

結論:

  • DATに対するTAAR1アゴニストの直接的およびTAAR1媒介的効果には臨床的に重要な差異がある.
  • 各アゴニスト (RO5166017,RO5256390,ulotaront) は,DATにおいて独特の薬理学プロファイルを示した.
  • これらの独特なメカニズムは,TAAR1アゴニストの治療設計と臨床適用において考慮されるべきである.